Skip to main content

US Genomics Lands $4.5M Equity Investment from BD for Pathogen Detection Tech

NEW YORK (GenomeWeb News) – US Genomics said today that Becton Dickinson has taken a $4.5 million equity investment in the firm, and the two companies will collaborate to develop a molecular diagnostic test for infectious disease.
 
Under the collaboration, the companies will develop US Genomics’ DirectLinear Analysis technology for use in a test that will detect a range of pathogens based on genotype.
 
A test based on the DLA technology, which integrates labeling, microfluidics, and optics, could identify a pathogen and test for virulence and drug resistance in a sample within hours, as opposed to several days, US Genomics said.
 
The test could help doctors predict what drugs a pathogen may be resistant to, and which drugs might make the most effective treatment, the company added.
 
US Genomics said that it has so far invested more than $50 million in developing the DLA technology, with support from venture funding, the US Department of Homeland Security, the National Science Foundation, and the Defense Advanced Research Projects Agency.
 
US Genomics’ CEO, John Canepa, said in a statement that DLA’s uses include bio-security, bio-surveillance, and environmental and food safety testing.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.